In the midst of a deadly opioid crisis, Ohio sues drugmakers for marketing fraud In a new lawsuit filed on Wednesday, Ohio’s attorney general is going after Teva, Allergan, Johnson […]
Eli Lilly’s Cyramza fuels expansion quest with positive bladder cancer showing Eli Lilly’s had mixed results in its quest to expand cancer blockbuster hopeful Cyramza. But the data from its […]
Teva posts positive phase 3 migraine data, plots FDA submission Israeli pharma Teva has hit its endpoints in the phase 3 Halo study of fremanezumab in migraines as it looks […]
Chiltern buys Japanese CRO IDA, boosting its Asia footprint Chiltern has acquired Japanese CRO Integrated Development Associates (IDA), strengthening its presence in Asia. Source: FierceMedicalDevices News Chiltern buys Japanese CRO […]
Gemphire’s CEO resigns for ‘personal reasons,’ plots new entrepreneurial ops Gemphire’s CEO and president Mina Sooch has resigned for “personal reasons” less than a year after helping get its cut-price […]
Swiss biotech NLS touts positive ADHD data, plots late-stage tests NLS Pharma has posted some positive data for its ADHD candidate mazindol CR, which it hopes will have better luck […]
Pfizer’s Trumenba to challenge GlaxoSmithKline’s Bexsero with EU nod Meningococcal B vaccine Bexsero has been helping drive revenue growth for GlaxoSmithKline, but now, with a European approval, Pfizer’s Trumenba is […]
AstraZeneca puts Brilinta, Bydureon on pay-for-performance bandwagon with Harvard Pilgrim deals Pay-for-performance deals have been gaining popularity among drugmakers eager to snag payer favor for their meds, and Harvard Pilgrim […]
Lawsuit says Novo, OptumRx ‘mutually benefited’ from rebate scheme, while consumers paid the price Novo Nordisk is the target, along with pharmacy benefit manager OptumRX, of a new proposed class […]
Roche, Boehringer tout new idiopathic pulmonary fibrosis analyses to boost their rival medications The idiopathic pulmonary fibrosis market-share battle between Roche’s Esbriet and Boehringer Ingelheim’s Ofev hasn’t let up since […]